Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (NYSEAM:PTHS) on April 1, 2026 with an Overweight rating and a price forecast implying 191.67% upside. The initiation is a materially positive analyst signal for the small-cap biotech and could drive near-term buying interest in the stock. Impact is primarily idiosyncratic to PTHS rather than market-wide.
Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (NYSEAM:PTHS) on April 1, 2026 with an Overweight rating and a price forecast implying 191.67% upside. The initiation is a materially positive analyst signal for the small-cap biotech and could drive near-term buying interest in the stock. Impact is primarily idiosyncratic to PTHS rather than market-wide.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
